Amy P. Murtha, MD, HS’92-’98, has been honored with a 2025 Distinguished Alumni Award by the Duke Medical Alumni Association for her sustained commitment to improving maternal-fetal health and advancing academic medicine.

Steven M. Scott, MD, HS’74-78, has been named the recipient of the 2025 Distinguished Service Award by the Duke Medical Alumni Association in recognition of his selfless service, steadfast passion for Duke, and transformative contributions to education, college athletics and health care institutions.

Pamela S. Douglas, MD, has been named a recipient of a 2025 Distinguished Faculty Award by the Duke Medical Alumni Association in recognition of her pioneering contributions to the field of cardiology.

Lori J. Pierce, MD’85, has been named the recipient of a Distinguished Alumni Award by the Duke Medical Alumni Association in recognition of her pioneering work in advancing breast cancer treatment and her leadership in education and training.

Joseph Heitman, MD, PhD, has been named the recipient of a 2025 Distinguished Faculty Award by the Duke Medical Alumni Association in recognition of his significant contributions to biomedical science, education, clinical impact, and leadership.

Cameron R. Wolfe, MD, HS’07-’08, professor of medicine in the Division of Infectious Diseases at Duke University, has been named a recipient of a Duke Medical Alumni Association 2025 Distinguished Faculty Award in recognition of his sustained contributions to clinical care, research, education, and institutional leadership.

Technological advances such as artificial intelligence, big data, and gene editing have dramatically accelerated the pace of biomedical research and health care. It can be hard to predict what new developments will arise next week, much less in the next 10, 50, or 100 years.

Tomi Akinyemiju, PhD, is a professor in the Department of Population Health Sciences. She emphasizes the importance of prevention and health equity in epidemiology and advocates for personalized approaches, leveraging big data and AI for risk prediction, and ensuring equitable access to medical and policy solutions to address health disparities.

Nicole Calakos, MD, PhD, is the Lincoln Financial Group Distinguished Professor of Neurobiology and specializes in synaptic physiology research and Parkinson’s disease and other movement disorders. She highlights the transformative impact of big data, AI, and cell modeling on neuroscience research, emphasizing the potential for advances in regenerative therapies and neural prostheses.

Dr. Michael Kastan, director of the Duke Cancer Institute, highlights the progress in cancer diagnosis and treatment, emphasizing prevention, screening, and personalized medicine. He envisions future advancements through genetic and biochemical discoveries, improved technologies, and targeted therapies, fulfilling DCI's mission to revolutionize cancer care.